

Supplementary Material for the article

“Epidemiology of Pain among Outpatients in Methadone Maintenance Treatment Programs”

Lara Dhingra,¹ Carmen Masson,² David C. Perlman,^{3,4,5}
Randy M. Seewald,⁴ Judith Katz,⁶ Courtney McKnight,^{3,5}
Peter Homel,⁷ Emily Wald,⁸ Ashly E. Jordan,³ Christopher Young,³
Russell K. Portenoy,⁹

¹ Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, Departments of Neurology and Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461

² Department of Psychiatry, University of California at San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110

³ Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003

⁴ Department of Medicine, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003

⁵ Center for Drug Use and HIV Research, New York University College of Nursing, 726 Broadway, New York, NY 10003

⁶ New York University School of Medicine, 550 First Avenue, New York, NY 10016

⁷ Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, NY 11219

⁸ Columbia Teacher's College, 525 West 120th Street, New York, NY 10027

⁹ Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, Departments of Neurology and Anesthesiology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461

Address for correspondence and reprints:

Lara K. Dhingra, Ph.D.
Department of Pain Medicine and Palliative Care
Beth Israel Medical Center
120 East 16th Street, 12th Floor
New York, NY 10003
Tel: 212 844 1429
Fax: 212 844 1503
Email: Ldhingra@chpnet.org

This material supplements but does not replace the content of the peer-reviewed paper published in *Drug and Alcohol Dependence*

Supplementary Table.

Sociodemographic, substance use and psychosocial characteristics of outpatients undergoing opioid agonist therapy for addiction ($N = 489$)

Characteristic	Sample, n (%)
Women ^a	155 (31.8)
Age (mean \pm standard deviation)	45.1 \pm 10.0
Racial/ethnic status	
Non-Hispanic Black	144 (29.4)
Non-Hispanic White	176 (36.0)
Hispanic	148 (30.3)
Other	21 (4.3)
Education level	
No high school degree	160 (32.7)
High school degree/higher	329 (67.3)
Income level (annual) ^b	
< \$10,000	298 (61.6)
\geq \$10,000	186 (38.4)
Employment status	
Employed	78 (15.9)
Unemployed	369 (75.5)
Retired/homemaker/student	42 (8.6)
Marital status	
Married	79 (16.2)
Unmarried	410 (83.8)
Months enrolled in MMTP (mean \pm SD)	34.9 \pm 59.4
Current methadone dose (mg) ^c	95.7 \pm 48.9
Intravenous drug use (current & former)	343 (70.1)
Endorsed use of illicit drugs in past 30 days	
Heroin	163 (33.3)
Cocaine	209 (42.7)
Amphetamines	36 (7.4)
Positive urine drug screening (at study enrollment)	
Opiates ^d	161 (32.9)
Cocaine	196 (40.1)
Amphetamines ^e	14 (2.9)

Homeless in past 6 months	
Yes	199 (40.7)
No	290 (59.3)
Live with partner	
Yes	162 (33.1)
No	327 (66.9)
BDI-II	
Minimal/mild ^f	260 (53.2)
Moderate/severe	229 (46.8)
MOS-SF-12	
MCS	38.9 ± 13.2
PCS	46.6 ± 8.8

Abbreviations: MMTP, Methadone Maintenance Treatment Program; BDI-II, Beck Depression Inventory-II; MOS-SF-12, Medical Outcomes Survey-Short Form; MCS, Mental Components Summary Score; PCS, Physical Components Summary Score, controlled for bodily pain.

^{a,b}Sample sizes for: sex, $n = 487$; income, $n = 484$; ^cmethadone dose, $n = 488$. ^dIncluding heroin, codeine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone. ^eIncluding amphetamine, methamphetamine, ecstasy. ^fCutoff scores: minimal = 0-13; mild = 14-19; moderate = 20-28; severe = 29-63.